StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Farxiga / Forxiga (dapagliflozin) by Quarter

Farxiga / Forxiga (dapagliflozin) — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Farxiga / Forxiga (dapagliflozin): $83M in Q2 2026, down 21.7% from a year earlier.

Latest, Q2 2026
83
Period ended Jun 30, 2026
Change on a year earlier
-21.7%
106 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Farxiga | | 1,804 | | ( 16 ) | | ( 19 ) | | 219 | | ( 48 ) | | 694 | | ( 19 ) | | ( 24 ) | | 808 | | 6 | | 1 | | 83 | | ( 22 ) | | ( 19 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFarxiga / Forxiga (dapagliflozin) — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202683-21.7%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202642-65.0%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202578-23.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025102-4.7%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025106+2.9%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025120+11.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024102+43.7%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024107+3.9%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024103-23.1%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024108-3.6%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023710.0%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023103+24.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023134+39.6%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023112+14.3%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202271-7.8%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202283+36.1%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up farxiga / Forxiga (dapagliflozin)

Cite this data

StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-farxiga-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?